TRICARE

How TRICARE approaches GLP-1 coverage

TRICARE pharmacy benefits are administered by Express Scripts under a Uniform Formulary that tiers medications and applies step therapy and prior-authorization rules. For type 2 diabetes, semaglutide (Ozempic, Rybelsus) and tirzepatide (Mounjaro) are generally available when prescribers document a confirmed T2D diagnosis, recent A1c, and prior or contraindicated trial of metformin; verify with your specific plan and current year formulary. For chronic weight management, TRICARE coverage of agents such as Wegovy, Zepbound, and Saxenda is more limited and requires prior authorization, a qualifying BMI (typically =30, or =27 with weight-related comorbidity), and documented participation in a structured lifestyle or behavioral intervention. Coverage can shift each plan year and may differ between active duty, retiree, TRICARE For Life, and Select beneficiaries, so beneficiaries should confirm formulary status, copays, and PA criteria with Express Scripts or a military treatment facility pharmacy before filling.

Statutory and structural notes

TRICARE pharmacy benefits are authorized under 10 U.S.C. §1074g and implemented through 32 CFR Part 199.21, which establishes the Uniform Formulary and Pharmacy and Therapeutics Committee process. Unlike Medicare Part D — which statutorily excludes weight-loss drugs under the Medicare Modernization Act of 2003 (SSA §1860D-2(e)(2)(A)) — TRICARE is not bound by that exclusion and may cover anti-obesity medications when clinical criteria are met.

Typically considered for coverage

The list below reflects general patterns observed across TRICAREplan documents. Coverage for any specific drug, dose, or indication must be confirmed against your own plan's current formulary and medical policy.

• Semaglutide (Ozempic) for type 2 diabetes with documented A1c and prior metformin trial — may be considered for coverage; verify with your specific plan and current formulary.
• Tirzepatide (Mounjaro) for type 2 diabetes when step therapy criteria are met — may be considered for coverage; verify with your specific plan and current formulary.
• Oral semaglutide (Rybelsus) for type 2 diabetes — may be considered for coverage; verify with your specific plan and current formulary.
• Wegovy (semaglutide 2.4 mg) for chronic weight management with qualifying BMI and documented lifestyle intervention — may be considered for coverage; verify with your specific plan and current formulary.
• Zepbound (tirzepatide) for chronic weight management or obstructive sleep apnea with obesity — may be considered for coverage; verify with your specific plan and current formulary.

Typically excluded

• Compounded semaglutide and tirzepatide — not FDA-approved as finished products and generally not covered by TRICARE.
• GLP-1 prescriptions written for cosmetic weight loss without medical necessity or qualifying BMI/comorbidity documentation.
• Quantities exceeding FDA-labeled dosing or refills outside formulary step therapy rules.
• Use of weight-management GLP-1s without prior authorization or without an enrolled lifestyle/behavioral component when required.

Prior authorization

Prior authorization is commonly required for GLP-1 medications under TRICARE plans. Your prescriber typically submits a PA form with diagnosis codes, lab results (e.g., A1c for T2D, BMI for weight management), documented prior therapy attempts, and clinical justification.

Appeal strategy if denied

If Express Scripts denies coverage, beneficiaries can request a formulary exception or medical-necessity review, then file a formal appeal through the TRICARE pharmacy appeals process (typically within 90 days of denial). Include a prescriber letter of medical necessity, A1c labs or BMI/comorbidity documentation, prior-therapy history, and relevant guideline citations. Military treatment facility pharmacists and patient advocates can assist.

GLP1Zoom is not an insurance company, broker, or health plan. We summarize general payer patterns from public plan documents and statute to help you ask the right questions. Always verify current coverage with your plan's member services. Full disclaimer.